KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for TherapeuticsMD (TXMD) over the last 8 years, with Q3 2025 value amounting to $871000.0.

  • TherapeuticsMD's Other Non-Current Liabilities rose 2354.61% to $871000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $871000.0, marking a year-over-year increase of 2354.61%. This contributed to the annual value of $744000.0 for FY2024, which is 1698.11% up from last year.
  • Latest data reveals that TherapeuticsMD reported Other Non-Current Liabilities of $871000.0 as of Q3 2025, which was up 2354.61% from $832000.0 recorded in Q2 2025.
  • TherapeuticsMD's Other Non-Current Liabilities' 5-year high stood at $2.1 million during Q4 2021, with a 5-year trough of $358000.0 in Q2 2021.
  • Its 5-year average for Other Non-Current Liabilities is $891111.1, with a median of $776500.0 in 2021.
  • As far as peak fluctuations go, TherapeuticsMD's Other Non-Current Liabilities skyrocketed by 206571.43% in 2021, and later plummeted by 4824.68% in 2022.
  • Over the past 5 years, TherapeuticsMD's Other Non-Current Liabilities (Quarter) stood at $2.1 million in 2021, then crashed by 48.25% to $1.1 million in 2022, then tumbled by 42.55% to $636000.0 in 2023, then increased by 16.98% to $744000.0 in 2024, then increased by 17.07% to $871000.0 in 2025.
  • Its Other Non-Current Liabilities was $871000.0 in Q3 2025, compared to $832000.0 in Q2 2025 and $795000.0 in Q1 2025.